KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to -$128.6 million.

  • Ionis Pharmaceuticals' Income from Continuing Operations rose 845.24% to -$128.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$257.0 million, marking a year-over-year increase of 2852.59%. This contributed to the annual value of -$454.5 million for FY2024, which is 2384.37% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Income from Continuing Operations of -$128.6 million as of Q3 2025, which was up 845.24% from $123.6 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Income from Continuing Operations registered a high of $223.7 million during Q4 2021, and its lowest value of -$147.4 million during Q3 2023.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$85.3 million (2023), whereas its average is -$67.0 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Income from Continuing Operations tumbled by 94959.52% in 2024 and then soared by 28644.99% in 2025.
  • Ionis Pharmaceuticals' Income from Continuing Operations (Quarter) stood at $223.7 million in 2021, then tumbled by 123.66% to -$52.9 million in 2022, then surged by 81.1% to -$10.0 million in 2023, then crashed by 949.6% to -$105.0 million in 2024, then decreased by 22.47% to -$128.6 million in 2025.
  • Its Income from Continuing Operations was -$128.6 million in Q3 2025, compared to $123.6 million in Q2 2025 and -$146.9 million in Q1 2025.